inspection – Page 271

Unplanned hold time extension during inspection preparation – root cause analysis failure explained

Investigation into Unplanned Hold Time Extensions During Inspection Preparations In the highly regulated pharmaceutical industry, any deviation from established protocols can lead to significant regulatory scrutiny. This case study details…

Equipment used without release during routine manufacturing – regulatory impact assessment case study

Investigating Equipment Utilization Without Release in Routine Pharmaceutical Manufacturing In the ever-evolving pharmaceutical industry, ensuring compliance with regulatory requirements is paramount. A critical issue arose when a major pharmaceutical company…

Equipment used without release during routine manufacturing – regulatory impact assessment case study

Case Study on Equipment Utilization Without Release in Routine Pharmaceutical Manufacturing In the landscape of pharmaceutical manufacturing, strict adherence to regulatory guidelines is imperative, especially when it comes to the…

Batch executed with expired SOP during commercial campaign – regulatory impact assessment case study

Regulatory Impact of Executing a Batch with Expired SOPs: A Case Study In the highly regulated environment of pharmaceutical manufacturing, strict adherence to Standard Operating Procedures (SOPs) is paramount. This…

Batch executed with expired SOP during commercial campaign – regulatory impact assessment case study

Case Study: Regulatory Impact Assessment of a Batch Executed with an Expired SOP in a Commercial Campaign In an environment where precision is paramount, the execution of a batch under…

Critical IPC skipped during routine manufacturing – CAPA ineffectiveness identified

Investigation of a Critical IPC Skipped During Routine Manufacturing: A Case Study In the fast-paced world of pharmaceutical manufacturing, adherence to standard operating procedures (SOPs) is paramount. Unfortunately, discrepancies can…

Critical IPC skipped during routine manufacturing – CAPA ineffectiveness identified

Lessons Learned from a Critical IPC Skipped During Routine Manufacturing The pharmaceutical manufacturing process is intricate and tightly regulated, where a minor deviation can lead to significant consequences. This case…

Unapproved process parameter change during tech transfer – CAPA ineffectiveness identified

Analysis of Unapproved Process Parameter Changes During Tech Transfer The pharmaceutical industry is governed by strict regulatory standards to ensure product safety and efficacy. However, deviations can occur, leading to…

Critical IPC skipped during changeover – regulatory impact assessment case study

Investigation of Skipped Critical IPC During Changeover: Insights from a Regulatory Impact Assessment In the world of pharmaceutical manufacturing, adherence to standardized operating procedures (SOPs) is paramount. This case study…

Deviation closed without effectiveness check during changeover – root cause analysis failure explained

Investigation of a Deviation Closed without Effectiveness Check During Changeover In the pharmaceutical manufacturing sector, ensuring compliance with Good Manufacturing Practices (GMP) is paramount. An unresolved deviation during a critical…

Equipment used without release during changeover – FDA inspection observation breakdown

Breakdown of FDA Inspection Observations Regarding Equipment Used Without Release During Changeover In the ever-vigilant arena of pharmaceutical manufacturing, regulatory compliance is paramount. A recent FDA inspection highlighted a significant…

Deviation recurrence across batches during scale-up – regulatory impact assessment case study

Investigating Deviation Recurrence During Scale-Up: A Regulatory Perspective In pharmaceutical manufacturing, scale-up processes often expose underlying inefficiencies or failures. One crucial challenge that many manufacturers encounter is the recurrence of…